Twist Bioscience opened lower at $162.94, compared with its previous close of $173.45. In the last trading session, the stock traded between $148.00 and $167.27. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Twist Bioscience is now worth
$ 126.22
giving a profit of
$ 26.22 (26.22%)
Note: Past profits do not guarantee future returns.
Rating from 10 Analysts
Today's Change
$-23.50 (-13.55%)
Day High
$167.27
Day Low
$148.00
Day Open
$162.94
Prev Close
$173.45
Volume
20,56,225
1W Return
10.73%
1M Return
-19.49%
3M Return
75.68%
6M Return
164.46%
1Y Return
365.54%
Market Cap ($ Mn)
9,871
PE Ratio
-
PB Ratio
19.87
PEG Ratio
-
ROE
-16.74%
ROCE
-16.30%
EPS (TTM)
$-0.56
1 Week
10.73%
1 Month
-19.49%
3 Months
75.68%
6 Months
164.46%
9 Months
260.63%
TD Cowen raises Twist Bioscience price target to $190, maintains Buy
TD Cowen maintains a Buy rating on Twist Bioscience. Price target raised from $115 to $190. Analyst Brendan Smith leads the coverage update.
17 days agoTwist Bioscience shares deliver 15.78% annualized return over five years
Average annual return of 15.78% over the last five years. Outperformed the market by 3.68% on an annualized basis. $1,000 investment grew to $2,041.63 at current price of $205.00. Current market capitalization stands at $13.50 billion.
24 days agoTwist Bioscience shares slip after touching fresh 52-week high
Twist Bioscience shares fell 0.98% to $182.22 after touching a fresh 52-week high near $192. The stock has gained more than 100% over the past nine weeks, rising from about $80. Recent price action shows five distinct rally legs with typical pullbacks of 10% to 15%. Shares are trading near the reported 52-week high of $185.22.
1mo agoTwist Bioscience secures data pipeline role in Eli Lilly TuneLab
Twist Bioscience partners with Eli Lilly’s TuneLab to provide antibody characterization data services. The deal supports AbLab, an antibody developability prediction model within the TuneLab ecosystem. Twist leverages high-throughput capabilities to generate training data for AI-driven drug discovery. Shares rose 5.79% to $146.09, approaching the 52-week high of $155.44.
1mo agoTwist Bioscience hits 52-week high as Anthropic deal overshadows short report
Twist Bioscience shares surged 22.64% to $142.39, hitting a new 52-week high after Anthropic selected it for a protein design campaign. The rally persisted despite a critical short report from Scorpion Capital questioning the partnership's materiality and citing deflationary risks from improved AI accuracy.
2mo agoTwist Bioscience raises FY26 sales guidance to $456M-$457M
Twist Bioscience reported Q3FY26 revenue of $118.376M, beating estimates, while missing EPS targets. The company raised full-year guidance to $456M-$457M and expects EBITDA breakeven in Q4, driven by growth in DNA synthesis and AI drug discovery opportunities.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 |
An investment of $100 made 5 years ago in Twist Bioscience is now worth
$ 126.22
giving a profit of
$ 26.22 (26.22%)
Note: Past profits do not guarantee future returns.
